Literature DB >> 33531462

Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need.

Pengfei Jin1, Jingxin Li1,2, Hongxing Pan1, Yanfei Wu3, Fengcai Zhu4,5,6.   

Abstract

In response to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, over 200 vaccine candidates against coronavirus disease 2019 (COVID-2019) are under development and currently moving forward at an unparalleled speed. The availability of surrogate endpoints would help to avoid large-scale filed efficacy trials and facilitate the approval of vaccine candidates, which is crucial to control COVID-19 pandemic. Several phase 3 efficacy trials of COVID-19 vaccine candidates are under way, which provide opportunities for the determination of COVID-19 correlates of protection. In this paper, we review current knowledge for existence of COVID-19 correlates of protection, methods for assessment of immune correlates of protection and issues related to COVID-19 correlates of protection.

Entities:  

Year:  2021        PMID： 33531462     DOI： 10.1038/s41392-021-00481-y

Source DB:  PubMed          Journal:  Signal Transduct Target Ther        ISSN： 2059-3635


  44 in total

1.  Nomenclature for immune correlates of protection after vaccination.

Authors:  Stanley A Plotkin; Peter B Gilbert
Journal:  Clin Infect Dis       Date:  2012-03-20       Impact factor: 9.079

2.  A framework for assessing immunological correlates of protection in vaccine trials.

Authors:  Li Qin; Peter B Gilbert; Lawrence Corey; M Juliana McElrath; Steven G Self
Journal:  J Infect Dis       Date:  2007-10-02       Impact factor: 5.226

3.  Correlates, surrogates, and vaccines.

Authors:  Jerald C Sadoff; Janet Wittes
Journal:  J Infect Dis       Date:  2007-10-02       Impact factor: 5.226

Review 4.  Fast vaccine design and development based on correlates of protection (COPs).

Authors:  Cécile van Els; Siri Mjaaland; Lisbeth Næss; Julia Sarkadi; Eva Gonczol; Karen Smith Korsholm; Jon Hansen; Jørgen de Jonge; Gideon Kersten; Jennifer Warner; Amanda Semper; Corine Kruiswijk; Fredrik Oftung
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques.

Authors:  Wei Deng; Linlin Bao; Jiangning Liu; Chong Xiao; Jiayi Liu; Jing Xue; Qi Lv; Feifei Qi; Hong Gao; Pin Yu; Yanfeng Xu; Yajin Qu; Fengdi Li; Zhiguang Xiang; Haisheng Yu; Shuran Gong; Mingya Liu; Guanpeng Wang; Shunyi Wang; Zhiqi Song; Ying Liu; Wenjie Zhao; Yunlin Han; Linna Zhao; Xing Liu; Qiang Wei; Chuan Qin
Journal:  Science       Date:  2020-07-02       Impact factor: 47.728

6.  SARS-CoV-2 infection protects against rechallenge in rhesus macaques.

Authors:  Abishek Chandrashekar; Jinyan Liu; Amanda J Martinot; Katherine McMahan; Noe B Mercado; Lauren Peter; Lisa H Tostanoski; Jingyou Yu; Zoltan Maliga; Michael Nekorchuk; Kathleen Busman-Sahay; Margaret Terry; Linda M Wrijil; Sarah Ducat; David R Martinez; Caroline Atyeo; Stephanie Fischinger; John S Burke; Matthew D Slein; Laurent Pessaint; Alex Van Ry; Jack Greenhouse; Tammy Taylor; Kelvin Blade; Anthony Cook; Brad Finneyfrock; Renita Brown; Elyse Teow; Jason Velasco; Roland Zahn; Frank Wegmann; Peter Abbink; Esther A Bondzie; Gabriel Dagotto; Makda S Gebre; Xuan He; Catherine Jacob-Dolan; Nicole Kordana; Zhenfeng Li; Michelle A Lifton; Shant H Mahrokhian; Lori F Maxfield; Ramya Nityanandam; Joseph P Nkolola; Aaron G Schmidt; Andrew D Miller; Ralph S Baric; Galit Alter; Peter K Sorger; Jacob D Estes; Hanne Andersen; Mark G Lewis; Dan H Barouch
Journal:  Science       Date:  2020-05-20       Impact factor: 47.728

Review 7.  Immunology of COVID-19: Current State of the Science.

Authors:  Nicolas Vabret; Graham J Britton; Conor Gruber; Samarth Hegde; Joel Kim; Maria Kuksin; Rachel Levantovsky; Louise Malle; Alvaro Moreira; Matthew D Park; Luisanna Pia; Emma Risson; Miriam Saffern; Bérengère Salomé; Myvizhi Esai Selvan; Matthew P Spindler; Jessica Tan; Verena van der Heide; Jill K Gregory; Konstantina Alexandropoulos; Nina Bhardwaj; Brian D Brown; Benjamin Greenbaum; Zeynep H Gümüş; Dirk Homann; Amir Horowitz; Alice O Kamphorst; Maria A Curotto de Lafaille; Saurabh Mehandru; Miriam Merad; Robert M Samstein
Journal:  Immunity       Date:  2020-05-06       Impact factor: 31.745

8.  Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19.

Authors:  Takuya Sekine; André Perez-Potti; Olga Rivera-Ballesteros; Kristoffer Strålin; Jean-Baptiste Gorin; Annika Olsson; Sian Llewellyn-Lacey; Habiba Kamal; Gordana Bogdanovic; Sandra Muschiol; David J Wullimann; Tobias Kammann; Johanna Emgård; Tiphaine Parrot; Elin Folkesson; Olav Rooyackers; Lars I Eriksson; Jan-Inge Henter; Anders Sönnerborg; Tobias Allander; Jan Albert; Morten Nielsen; Jonas Klingström; Sara Gredmark-Russ; Niklas K Björkström; Johan K Sandberg; David A Price; Hans-Gustaf Ljunggren; Soo Aleman; Marcus Buggert
Journal:  Cell       Date:  2020-08-14       Impact factor: 41.582

9.  Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate.

Authors:  Amin Addetia; Katharine H D Crawford; Adam Dingens; Haiying Zhu; Pavitra Roychoudhury; Meei-Li Huang; Keith R Jerome; Jesse D Bloom; Alexander L Greninger
Journal:  J Clin Microbiol       Date:  2020-10-21       Impact factor: 5.948

10.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

Authors:  Fernando P Polack; Stephen J Thomas; Nicholas Kitchin; Judith Absalon; Alejandra Gurtman; Stephen Lockhart; John L Perez; Gonzalo Pérez Marc; Edson D Moreira; Cristiano Zerbini; Ruth Bailey; Kena A Swanson; Satrajit Roychoudhury; Kenneth Koury; Ping Li; Warren V Kalina; David Cooper; Robert W Frenck; Laura L Hammitt; Özlem Türeci; Haylene Nell; Axel Schaefer; Serhat Ünal; Dina B Tresnan; Susan Mather; Philip R Dormitzer; Uğur Şahin; Kathrin U Jansen; William C Gruber
Journal:  N Engl J Med       Date:  2020-12-10       Impact factor: 91.245
View more
  31 in total

Review 1.  Proteomics advances towards developing SARS-CoV-2 therapeutics using in silico drug repurposing approaches.

Authors:  Amrita Mukherjee; Ayushi Verma; Surbhi Bihani; Ananya Burli; Krishi Mantri; Sanjeeva Srivastava
Journal:  Drug Discov Today Technol       Date:  2021-06-24

2.  Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection.

Authors:  Romain Marlin; Mélanie Prague; Marie Alexandre; Severin Coleon; Nidhal Kahlaoui; Sylvain Cardinaud; Thibaut Naninck; Benoit Delache; Mathieu Surenaud; Mathilde Galhaut; Nathalie Dereuddre-Bosquet; Mariangela Cavarelli; Pauline Maisonnasse; Mireille Centlivre; Christine Lacabaratz; Aurelie Wiedemann; Sandra Zurawski; Gerard Zurawski; Olivier Schwartz; Rogier W Sanders; Roger Le Grand; Yves Levy; Rodolphe Thiébaut
Journal:  Elife       Date:  2022-07-08       Impact factor: 8.713

3.  Highly feasible immunoprotective multicistronic SARS-CoV-2 vaccine candidate blending novel eukaryotic expression and Salmonella bactofection.

Authors:  Vijayakumar Jawalagatti; Perumalraja Kirthika; Ji-Young Park; Chamith Hewawaduge; John Hwa Lee
Journal:  J Adv Res       Date:  2021-07-22       Impact factor: 10.479

4.  Severe acquired haemophilia associated with asymptomatic SARS-CoV-2 infection.

Authors:  Kevin Y Wang; Pratik Shah; Dennis T Roarke; Shams A Shakil
Journal:  BMJ Case Rep       Date:  2021-07-20

5.  Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients.

Authors:  Mounzer Agha; Maggie Blake; Charles Chilleo; Alan Wells; Ghady Haidar
Journal:  medRxiv       Date:  2021-04-07

Review 6.  COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations.

Authors:  Qian He; Qunying Mao; Jialu Zhang; Lianlian Bian; Fan Gao; Junzhi Wang; Miao Xu; Zhenglun Liang
Journal:  Front Immunol       Date:  2021-04-12       Impact factor: 7.561

7.  Functional Antibodies in COVID-19 Convalescent Plasma.

Authors:  Jonathan D Herman; Chuangqi Wang; Carolin Loos; Hyunah Yoon; Johanna Rivera; M Eugenia Dieterle; Denise Haslwanter; Rohit K Jangra; Robert H Bortz; Katharine J Bar; Boris Julg; Kartik Chandran; Douglas Lauffenburger; Liise-Anne Pirofski; Galit Alter
Journal:  medRxiv       Date:  2021-03-11

Review 8.  COVID-19 vaccination in pediatric solid organ transplant recipients-Current state and future directions.

Authors:  Arnaud G L'Huillier; Monica I Ardura; Abanti Chaudhuri; Lara Danziger-Isakov; Daniel Dulek; Michael Green; Marian G Michaels; Klara M Posfay-Barbe; Luciola Vàsquez; Christian Benden
Journal:  Pediatr Transplant       Date:  2021-06-02

Review 9.  Correlates of Vaccine-Induced Protection against SARS-CoV-2.

Authors:  Till Koch; Sibylle C Mellinghoff; Parichehr Shamsrizi; Marylyn M Addo; Christine Dahlke
Journal:  Vaccines (Basel)       Date:  2021-03-10

10.  Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer.

Authors:  Amir Massarweh; Noa Eliakim-Raz; Amos Stemmer; Adva Levy-Barda; Shlomit Yust-Katz; Alona Zer; Alexandra Benouaich-Amiel; Haim Ben-Zvi; Neta Moskovits; Baruch Brenner; Jihad Bishara; Dafna Yahav; Boaz Tadmor; Tal Zaks; Salomon M Stemmer
Journal:  JAMA Oncol       Date:  2021-05-28       Impact factor: 31.777
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.